



NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS

**RAVENQUEST ANNOUNCES CLOSING OF CL2G GROUP ACQUISITION
AND PRIVATE PLACEMENT**

CSE - RVT

September 28, 2017 – Vancouver, BC, Canada

RavenQuest Biomed Inc., formerly Ravencrest Resources Inc., (the “**Company**”) [CSE – **RVT**] is pleased to announce that it has completed the acquisition of the principal assets and business operations of the CL2G group of companies (the “**CL2G Group**”), including an operating, turn-key fully equipped, cannabis operations training facility and related equipment (the “**CL2G Acquisition**”), previously announced on May 25, 2017, June 28, 2017 and September 8, 2017.

Following completion of the CL2G Acquisition, the Company has commenced operations as a specialized cannabis services provider, with a primary focus on providing management and advisory services to cannabis producers that are Licensed Producers or later stage LP Applicants under the *Access to Cannabis for Medical Producers Regulations* (the “**ACMPR**”). Future growth will focus on completing investments in and providing management services to other cannabis license applicants and license holders and ongoing research and development of proprietary cannabis growing technologies.

As consideration for the acquisition of the principal assets and business operations of the CL2G Group, the Company issued an aggregate of 8,080,000 common shares of the Company to the CL2G Group shareholders.

In connection with the closing of the CL2G Acquisition, the Company has appointed George Robinson as Chief Executive Officer and a director of the Company, David Cross as Chief Financial Officer, and Marla K. Ritchie as Corporate Secretary. Anton J. Drescher has resigned as President and Chief Executive Officer, but will remain on the Company’s board of directors.

The Company also completed a private placement of 21,000,000 common shares at a price of \$0.30 per share for aggregate proceeds of \$6,300,000 (the “**Private Placement**”). The primary uses of the Private Placement proceeds are intended to fund costs associated with the CL2G Acquisition and the AGB Acquisition discussed below, identification of other target acquisitions, development of the Company’s business, management and related party salaries, payment of trade debt, project construction, research and development and to fund general working capital. In connection with closing, the Company paid aggregate cash finder’s fees of \$388,359.88, representing 8% of the subscription proceeds received from certain arm’s length subscribers.

Directors and officers of the Company subscribed for an aggregate of 1,570,000 common shares under the Private Placement. Issuance of the shares to the directors and officers are “related party transactions” under Multilateral Instrument 61-101 *Protection of Minority Security Holders in Special Transactions* (“**MI 61-101**”). The Company is relying on exemptions from the minority shareholder approval and formal valuation

requirements applicable to the related party transactions under Sections 5.7(b) and 5.5(b), respectively, of MI 61-101. There has been no prior formal valuation of the common shares issued as there has not been any necessity to do so. The Private Placement has been reviewed and unanimously approved by the Company's board of directors, including the independent directors.

As disclosed in the Company's prior news releases, following completion of the CL2G Acquisition, the Company intends to acquire the outstanding share capital of Alberta Green Biotech Inc., a private arm's length entity incorporated in Alberta which has applied to become a licensed producer of cannabis for medical purposes under the ACMPR (the "AGB Acquisition").

The CL2G Acquisition, Private Placement and AGB Acquisition will constitute a Fundamental Change under the policies of the Canadian Securities Exchange (the "Exchange"). In accordance with Exchange policies, the Company has filed an Exchange Form 2A Listing Statement (the "Listing Statement") under its profile on the Exchange's website providing additional information regarding the CL2G Group, the Private Placement, AGB, and the Company following completion of the Fundamental Change.

Readers are encouraged to carefully read and review the disclosure contained in the Listing Statement. Investors are cautioned that, except as disclosed in the Listing Statement or other disclosure document of the Company prepared in connection with the Fundamental Change, any information released or received with respect to the transactions disclosed in this news release may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative. It is anticipated that trading in the Company's common shares on the Exchange will remain halted until completion of the AGB Acquisition. As previously announced in the Company's September 26, 2017 news release, it is anticipated that upon resumption of trading, the Company's trading symbol will be changed to "RQB".

George Robinson, CEO, commented "It is a privilege to be selected by the Board of Directors for this critical role. I wish to thank Tony Drescher for the years of service as CEO and I am pleased that he will remain on the Board of Directors. I look forward to working alongside the Company's directors Tony Drescher, Henk van Alphen, Chris Bechtel and Jorge Bonet. As we build the team together, I am proud to have Dave Cross and Marla Ritchie supporting the organization."

FOR FURTHER INFORMATION PLEASE CONTACT:

George Robinson
Chief Executive Officer
RavenQuest Biomed Inc.
(T) (604) 638-3886
E-mail: info@rqbglobal.com

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to the Fundamental Change and the transactions contemplated in connection therewith. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

UNITED STATES ADVISORY. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), have been offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.